Practice Pearls

What can we help you find?
The iStopMM Trial & Importance of Early Screening
Key opinion leaders discuss the iStopMM study and the importance of early screening.
The Role of Payers in the Dispensing Process
A discussion on the role of payers in the oral oncolytic dispensing process.
The Future of Oral Oncolytics
Expert panelists consider the future of the treatment of multiple myeloma, with oral oncolytics being the standard of therapy.
Pearl 4: Using a Collaborative Care Plan for the Treatment of MM
The panelists discuss the collaborative care plan in place for providing patients with the optimal treatment of multiple myeloma.
Difficulties of the Multiple Myeloma Treatment Continuum
Key opinion leaders expand upon the difficulties that arise from the oral oncolytic dispensary system, including the inadequacy of community centers, time-consuming documentation, the appropriate utilization contingencies, and more.
The Role of Specialty Pharmacies in the Dispensing Process
A discussion on the role of specialty pharmacies in the oral oncolytic distribution process and the difficulties of patients who are geographically challenged.
The Dispensing Capabilities of Pharmacies
Peter Salgo, MD, et al., consider the dispensing capabilities of pharmacies in addition to 7-days-off treatment plans.
Pearl 3: Avoiding Delays During Prior Authorization Process
Key opinion leaders discuss the policy of prior authorization and how it may affect the timely delivery of oral oncolytic therapy.
The Risk Evaluation and Mitigation Strategies (REMS) Program
The panel defines the REMS program and the criteria for obtaining authorization.
Pearl 1: Oral Parity Laws and Their Impact on Cost
A discussion on the oral parity laws and their impact on costs.
Pearl 1: The Use of Co-Pay Cards to Solve an Economic Burden
Peter Salgo, MD, leads a discussion on the use of commercial co-pay cards to mitigate the financial burden of oral oncolytics.
Medicare Coverage of Oral Oncolytics
Key opinion leaders compare Medicare Part B with Medicare Part D, and consider the effectiveness of Medicare Part D to offset the cost of oral oncolytic treatment.
+ Load More